Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Weber

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
The Lancet. Neurology|February 4, 2018
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional managementDavid J Birnkrant, Katharine Bushby, Carla M Bann, et al.
The Journal of Clinical Endocrinology and Metabolism|March 25, 2025
Race-Neutral Pediatric Reference Ranges for Bone Mineral Density Predict Prospective Fractures in ChildhoodBabette S Zemel, Karen K Winer, Andrea Kelly, et al.
Pediatric Blood & Cancer|May 17, 2023
Pathogenic variants in PIK3CA are associated with clinical phenotypes of kaposiform lymphangiomatosis, generalized lymphatic anomaly, and central conducting lymphatic anomalyJeremy M Grenier, Alexandra J Borst, Sarah E Sheppard, et al.
The Lancet. Neurology|February 6, 2018
Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespanDavid J Birnkrant, Katharine Bushby, Carla M Bann, et al.
Clinical Pediatrics|July 16, 2020
Long-Term Follow-up of Hypophosphatemic Bone Disease Associated With Elemental Formula Use: Sustained Correction of Bone Disease After Formula Change or Phosphate SupplementationAbigail S Eswarakumar, Nina S Ma, Leanne M Ward, et al.
Journal of Neuromuscular Diseases|February 20, 2025
A Parent Project Muscular Dystrophy-sponsored International Workshop Report on Endocrine and Bone Issues in Patients with Duchenne Muscular Dystrophy: An Ever-changing LandscapeLeanne M Ward, David R Weber, Sze Choong Wong, et al.
Journal of Neuromuscular Diseases|November 19, 2023
Moving Beyond the 2018 Minimum International Care Considerations for Osteoporosis Management in Duchenne Muscular Dystrophy (DMD): Meeting Report from the 3rd International Muscle-Bone Interactions Meeting 7th and 14th November 2022Kim Phung, Nicola Crabtree, Anne M Connolly, et al.
Bone|February 8, 2017
Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and childrenLuisa F Gonzalez Ballesteros, Nina S Ma, Rebecca J Gordon, et al.
Progress in Pediatric Cardiology|July 31, 2019
Use of advanced heart failure therapies in Duchenne muscular dystrophyCarol A Wittlieb-Weber, Chet R Villa, Jennifer Conway, et al.
Neurology. Genetics|September 3, 2025
Study of Testosterone and Recombinant Human Growth Hormone in Facioscapulohumeral Muscular DystrophyChad Rydel Heatwole, Elizabeth Luebbe, Johanna Hamel, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
The Lancet. Neurology|February 4, 2018
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional managementDavid J Birnkrant, Katharine Bushby, Carla M Bann, et al.
The Journal of Clinical Endocrinology and Metabolism|March 25, 2025
Race-Neutral Pediatric Reference Ranges for Bone Mineral Density Predict Prospective Fractures in ChildhoodBabette S Zemel, Karen K Winer, Andrea Kelly, et al.
Pediatric Blood & Cancer|May 17, 2023
Pathogenic variants in PIK3CA are associated with clinical phenotypes of kaposiform lymphangiomatosis, generalized lymphatic anomaly, and central conducting lymphatic anomalyJeremy M Grenier, Alexandra J Borst, Sarah E Sheppard, et al.
The Lancet. Neurology|February 6, 2018
Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespanDavid J Birnkrant, Katharine Bushby, Carla M Bann, et al.
Clinical Pediatrics|July 16, 2020
Long-Term Follow-up of Hypophosphatemic Bone Disease Associated With Elemental Formula Use: Sustained Correction of Bone Disease After Formula Change or Phosphate SupplementationAbigail S Eswarakumar, Nina S Ma, Leanne M Ward, et al.
Journal of Neuromuscular Diseases|February 20, 2025
A Parent Project Muscular Dystrophy-sponsored International Workshop Report on Endocrine and Bone Issues in Patients with Duchenne Muscular Dystrophy: An Ever-changing LandscapeLeanne M Ward, David R Weber, Sze Choong Wong, et al.
Journal of Neuromuscular Diseases|November 19, 2023
Moving Beyond the 2018 Minimum International Care Considerations for Osteoporosis Management in Duchenne Muscular Dystrophy (DMD): Meeting Report from the 3rd International Muscle-Bone Interactions Meeting 7th and 14th November 2022Kim Phung, Nicola Crabtree, Anne M Connolly, et al.
Bone|February 8, 2017
Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and childrenLuisa F Gonzalez Ballesteros, Nina S Ma, Rebecca J Gordon, et al.
Progress in Pediatric Cardiology|July 31, 2019
Use of advanced heart failure therapies in Duchenne muscular dystrophyCarol A Wittlieb-Weber, Chet R Villa, Jennifer Conway, et al.
Neurology. Genetics|September 3, 2025
Study of Testosterone and Recombinant Human Growth Hormone in Facioscapulohumeral Muscular DystrophyChad Rydel Heatwole, Elizabeth Luebbe, Johanna Hamel, et al.
Pageof 8